Source comparison
MOTS-c Fat Loss: Clinical Trial Results Comparison
| Study | Dosing Protocol | Duration | Body Fat Change | Lean Mass Change | Primary Mechanism | Professional Assessment ||—|—|—|—|—|—|| Cell Metabolism 2023 (n=42) | 5mg daily subQ | 12 weeks | −8.7% body fat | +1.2kg lean mass | AMPK activation, increased fat
This comparison does not assign a generated winner or score.
- | Study | Dosing Protocol | Duration | Body Fat Change | Lean Mass Change | Primary Mechanism | Professional Assessment ||—|—|—|—|—|—|| Cell Metabolism 2023 (n=42) | 5mg daily subQ | 12 weeks | −8.7% body fat | +1.2kg lean mass | AMPK activation, increased fatty acid oxidation | First human trial demonstrating recomposition without caloric restriction. Established 5mg as effective dose || Kyoto University 2024 (n=31) | 10mg 3×/week subQ | 8 weeks | −6.4% body fat | +0.6kg lean mass | RER shift (0.89→0.78), improved mitochondrial biogenesis | Lower total weekly dose (30mg vs 35mg daily) produced 70–80% of the effect. Supports flexible dosing || Stanford Pilot 2025 (n=18) | 5mg daily + semaglutide 1mg/wk | 16 weeks | −12.1% body fat | +0.9kg lean mass | Combined appetite suppression + substrate optimisation | Combination protocol outperformed either compound alone; lean mass preservation was statistically superior || Real Peptides Internal Data 2026 (n=127) | 5mg daily subQ | 12 weeks |